On the 21st, JW Shinyak announced that it will resume sales of SK Bioscience’s flu vaccine ‘SKYCellflu Quadrivalent Prefilled Syringe.’

The company signed a joint marketing agreement for ‘SKYCellflu Quadrivalent Prefilled Syringe’ in 2016, and has been responsible for the sales and marketing of the drug at specialized dermatology, urology, and plastic surgery clinics and hospitals.

SKYCellflu Quadrivalent Prefilled Syringe is the first cell culture-based influenza vaccine developed by SK Bioscience. It can protect against four types of influenza viruses, including 2 types of influenza A viruses and 2 types of influenza B viruses.

SK Bioscience has discontinued product